AU2019312144B2 - Small molecule ligand-targeted drug conjugates for anti-influenza chemotherapy and immunotherapy - Google Patents

Small molecule ligand-targeted drug conjugates for anti-influenza chemotherapy and immunotherapy Download PDF

Info

Publication number
AU2019312144B2
AU2019312144B2 AU2019312144A AU2019312144A AU2019312144B2 AU 2019312144 B2 AU2019312144 B2 AU 2019312144B2 AU 2019312144 A AU2019312144 A AU 2019312144A AU 2019312144 A AU2019312144 A AU 2019312144A AU 2019312144 B2 AU2019312144 B2 AU 2019312144B2
Authority
AU
Australia
Prior art keywords
zanamivir
conjugate
virus
infected
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019312144A
Other languages
English (en)
Other versions
AU2019312144A1 (en
Inventor
Xin Liu
Philip Stewart Low
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of AU2019312144A1 publication Critical patent/AU2019312144A1/en
Application granted granted Critical
Publication of AU2019312144B2 publication Critical patent/AU2019312144B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2019312144A 2018-07-26 2019-07-20 Small molecule ligand-targeted drug conjugates for anti-influenza chemotherapy and immunotherapy Active AU2019312144B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862703534P 2018-07-26 2018-07-26
US62/703,534 2018-07-26
US201962846549P 2019-05-10 2019-05-10
US62/846,549 2019-05-10
PCT/US2019/042715 WO2020023323A1 (en) 2018-07-26 2019-07-20 Small molecule ligand-targeted drug conjugates for anti-influenza chemotherapy and immunotherapy

Publications (2)

Publication Number Publication Date
AU2019312144A1 AU2019312144A1 (en) 2021-03-18
AU2019312144B2 true AU2019312144B2 (en) 2025-05-08

Family

ID=69180703

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019312144A Active AU2019312144B2 (en) 2018-07-26 2019-07-20 Small molecule ligand-targeted drug conjugates for anti-influenza chemotherapy and immunotherapy

Country Status (7)

Country Link
US (1) US20210393786A1 (https=)
EP (1) EP3826681A4 (https=)
JP (2) JP2021531312A (https=)
CN (1) CN112672762B (https=)
AU (1) AU2019312144B2 (https=)
CA (1) CA3107778A1 (https=)
WO (1) WO2020023323A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021210987A1 (en) * 2020-01-24 2022-08-04 Regeneron Pharmaceuticals, Inc. Protein-antiviral compound conjugates
US20210402001A1 (en) * 2020-06-30 2021-12-30 David I. Cohen Zinc Porters, and their Monoclonal Antibody Conjugates, for the Prevention and Treatment of COVID-19 (SARS-CoV-2), Other Infections, and Cancers
EP4175637A4 (en) * 2020-07-02 2024-08-07 Purdue Research Foundation Tetrahydro-3h-pyrazolo quinolone and tetrahydro-3h-pyrrolo[3,2-f]quinoline-containing compounds and uses thereof
WO2022015754A2 (en) * 2020-07-13 2022-01-20 University Of Southern California Universal car-nk cell targeting various epitopes of hiv-1 gp160
EP4337663A4 (en) * 2021-05-14 2026-04-15 Purdue Research Foundation BISPECIFIC SMALL MOLECULE-BASED IMMUNE CELL ATTACHMENTS AND THEIR USE IN THE TREATMENT OF ENVELOPED VIRUS INFECTION
MX2024000897A (es) * 2021-07-28 2024-02-06 Regeneron Pharma Conjugados de proteina y compuestos antivirales.
CN119403574A (zh) * 2022-04-19 2025-02-07 普渡研究基金会 双半抗原和三半抗原缀合物、组合物、制备方法及其治疗方法
CN116375647A (zh) * 2023-01-21 2023-07-04 兰州大学 一种基于Click反应的CAR-T细胞药物递送平台及其构建方法与应用
WO2025085664A1 (en) * 2023-10-17 2025-04-24 Mary Lynn Niedrauer Conjugates, com positions and methods for treating influenza
WO2025133395A1 (en) 2023-12-22 2025-06-26 Forx Therapeutics Ag Bicyclic (hetero)arylene wrn inhibitory compounds

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028411A1 (en) * 2000-10-06 2002-04-11 Xenoport, Inc. Compounds for sustained release of orally delivered drugs
US6692724B1 (en) * 1999-10-25 2004-02-17 Board Of Regents, The University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
WO2014100615A1 (en) * 2012-12-20 2014-06-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
US20150284416A1 (en) * 2015-06-16 2015-10-08 Suzhou M-Conj Biotech Co., Ltd Novel linkers for conjugation of cell-binding molecules
US9250238B2 (en) * 2010-06-25 2016-02-02 Purdue Research Foundation Pathogen detection
US20170102387A1 (en) * 2010-05-10 2017-04-13 Academia Sinica Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2518926T3 (es) * 2000-06-02 2014-11-05 Board Of Regents, The University Of Texas System Conjugados de etilendicisteína y un análogo de glucosa
CN102036658A (zh) * 2008-05-23 2011-04-27 香港大学 治疗流感的联合疗法
CA2790577A1 (en) * 2010-02-25 2011-09-01 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US10130714B2 (en) * 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
JP7282521B2 (ja) * 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6692724B1 (en) * 1999-10-25 2004-02-17 Board Of Regents, The University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
WO2002028411A1 (en) * 2000-10-06 2002-04-11 Xenoport, Inc. Compounds for sustained release of orally delivered drugs
US20170102387A1 (en) * 2010-05-10 2017-04-13 Academia Sinica Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
US9250238B2 (en) * 2010-06-25 2016-02-02 Purdue Research Foundation Pathogen detection
WO2014100615A1 (en) * 2012-12-20 2014-06-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
US20150284416A1 (en) * 2015-06-16 2015-10-08 Suzhou M-Conj Biotech Co., Ltd Novel linkers for conjugation of cell-binding molecules

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JENNIFER S. Y. MA ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 113, no. 4, 12 January 2016 (2016-01-12), pages E450 - E458, XP055678633, ISSN: 0027-8424, DOI: 10.1073/pnas.1524193113 *
STREICHER HANSJÖRG ET AL, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 24, no. 7, 18 February 2014 (2014-02-18), pages 1805 - 1807, XP028835157, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2014.02.021 *

Also Published As

Publication number Publication date
CA3107778A1 (en) 2020-01-30
JP2024029005A (ja) 2024-03-05
JP2021531312A (ja) 2021-11-18
EP3826681A1 (en) 2021-06-02
WO2020023323A1 (en) 2020-01-30
US20210393786A1 (en) 2021-12-23
EP3826681A4 (en) 2022-08-17
CN112672762B (zh) 2025-06-13
AU2019312144A1 (en) 2021-03-18
CN112672762A (zh) 2021-04-16

Similar Documents

Publication Publication Date Title
AU2019312144B2 (en) Small molecule ligand-targeted drug conjugates for anti-influenza chemotherapy and immunotherapy
AU2018218179B2 (en) Methods of treating influenza
Liao et al. Germacrone inhibits early stages of influenza virus infection
Wu et al. Progress of small molecular inhibitors in the development of anti-influenza virus agents
Zarubaev et al. Broad range of inhibiting action of novel camphor-based compound with anti-hemagglutinin activity against influenza viruses in vitro and in vivo
Tarbet et al. Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice
US20130205416A1 (en) Anti-viral agent
Haasbach et al. The NF-kappaB inhibitor SC75741 protects mice against highly pathogenic avian influenza A virus
CN102480967A (zh) 用于治疗流感的化合物和方法
Lin et al. Potent influenza A virus entry inhibitors targeting a conserved region of hemagglutinin
Hong et al. Morin hydrate inhibits influenza virus entry into host cells and has anti-inflammatory effect in influenza-infected mice
Tian et al. Dihydromyricetin is a new inhibitor of influenza polymerase PB2 subunit and influenza-induced inflammation
Hussein et al. Identification of entry inhibitors with 4-aminopiperidine scaffold targeting group 1 influenza A virus
Chen et al. The seafood Musculus senhousei shows anti-influenza A virus activity by targeting virion envelope lipids
Lv et al. Zanamivir–cholesterol conjugate: a long-acting neuraminidase inhibitor with potent efficacy against drug-resistant influenza viruses
Yang et al. Influenza virus entry inhibitors
JP2009242247A (ja) ヒト免疫不全ウイルス感染阻害剤およびエイズの治療薬または予防薬
HK40050842A (en) Small molecule ligand-targeted drug conjugates for anti-influenza chemotherapy and immunotherapy
Shen et al. An oligothiophene compound neutralized influenza A viruses by interfering with hemagglutinin
HK40050842B (zh) 用於抗流感化学治疗和免疫治疗的小分子配体靶向药物缀合物
Liu Small Molecule Ligand-Targeted Delivery of Therapeutic Agents for Treatment of Influenza Virus Infections
WO2019185521A1 (en) Ergosterol-biosynthesis inhibitor and influenza virus infection
CA3052503C (en) Methods of treating influenza
Sinha Insights into the Development of Antiviral Therapies for Influenza and New Nanoparticle-based Approaches of Treatment
Naesens et al. Intracytoplasmic Trapping of Influenza

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)